BioSpace News Archive

Merck’s KEYTRUDA ® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma.

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has appointed Mr. James Kinley as the Company’s Chief Financial Officer (“CFO”), effective December 1, 2021.

Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced it has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis.

Oncology Pharma Inc. is a pioneering oncology company dedicated to providing the financing and the tools to license, develop, manufacture, and commercialize therapeutics.

Inflammatix announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company’s board of directors.

T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, announced that biotech industry veteran Laura Brege has been appointed to the company’s Board of Directors.

aTyr Pharma, Inc. (Nasdaq: LIFE), and FUJIFILM Diosynth Biotechnologies, today announced a manufacturing agreement for ATYR1923, aTyr Pharma’s lead therapeutic candidate that is currently in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

Sciwind Biosciences Co., Ltd. announced that it has signed a global, exclusive license agreement with Sanofi to develop and commercialize Sanofi’s long-lasting glucose-dependent insulinotropic polypeptide receptor agonists, with the lead candidate currently under preclinical development.

NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced that the preclinical data on naptumomab estafenatox (NAP) enhancing the potency of CAR-T cells was presented on Nov 12th at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting at the Walter E. Washington Convention Center, Washington D.C.

Nevro Corp. today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 virtual meeting.